PadGau: Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation

Sponsor
CENTOGENE GmbH Rostock (Industry)
Overall Status
Completed
CT.gov ID
NCT01272687
Collaborator
(none)
1,500
15
77
100
1.3

Study Details

Study Description

Brief Summary

The genotype-phenotype correlation in patients with Parkinson's disease with specific mutations in the glucocerebrosidase gene (Gaucher gene) is known from own clinical experiences as well as from case reports in the literature. The epidemiological study will determine the frequency of heterozygous mutations in the glucocerebrosidase gene and correlate to the clinical onset and development by measuring and documenting severity of symptoms (e.g. cognitive deficits, L-dopa responsiveness, depression) in clinically well-characterized Parkinson's patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Parkinson's disease (also known as Parkinson's, Parkinson disease, or PD) is a degenerative disorder of the central nervous system that impairs motor skills, cognitive processes, and other functions. The most obvious symptoms are motor-related, including tremor, rigidity, slowness of movement, and postural instability. Among non-motor symptoms are autonomic dysfunction and sensory and sleep difficulties. Cognitive and neurobehavioral problems, including dementia, are common in the advanced stages of the disease. PD usually appears around the age of 60, although there are young-onset cases.

    Gaucher's disease is a genetic disease in which a fatty substance (lipid) accumulates in cells and certain organs. Gaucher's disease is the most common of the lysosomal storage diseases. It is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as acid β-glucosidase). The enzyme acts on a fatty substance glucocerebroside (also known as glucosylceramide). When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain and bone marrow.

    Symptoms of Parkinson's syndrome in classical type 1 Gaucher patients were first systematically described in 1996. In GD patients, a marked heterogeneity is detected in terms of disease-causing mutations. In 17 Gaucher patients with symptoms of Parkinson's disease, 12 different genotypes were sequenced and compared to other Parkinson's patients, a lower L-dopa responsiveness, a higher frequency of cortical dysfunction and a relatively early onset of the symptoms was described. Many of these Gaucher patients with clinical Parkinson's symptoms had a positive family history of Parkinson's disease among relatives with heterozygous mutations in the Gaucher gene that could be confirmed in systematic studies.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Epidemiological Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation
    Actual Study Start Date :
    Jan 1, 2011
    Actual Primary Completion Date :
    Jun 1, 2016
    Actual Study Completion Date :
    Jun 1, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    Observation

    Adults (>18 years) with a confirmed diagnosis of Parkinson's disease

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Male or female patients at 18 years old

      • Patients with confirmed diagnosis of Parkinson's disease

      • Signed informed consent

      Exclusion Criteria:
      • Male or female patients being younger than 18 years old

      • Patients without confirmed diagnosis of Parkinson's disease

      • Missing signed informed consent

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Fachkrankenhaus für neurologische Akut- und Rehabilitationsmedizin Bad Neustadt An Der Saale Germany 97616
      2 Universitätsklinikum Dresden Klinik für Neurologie Dresden Germany 01307
      3 University of Giessen, Department of Neurology Giessen Germany 35385
      4 Ernst-Moritz-Arndt-University of Greifswald, Department of Neurology Greifswald Germany 17489
      5 Universitätskrankenhaus Hamburg-Eppendorf, Department of Neurology Hamburg Germany 20246
      6 Medizinische Hochschule Hannover, Bewegungsstörungsambulanz Hannover Germany 30625
      7 Alexianer Krefeld GmbH, Krankenhaus Maria Hilf Krefeld Germany 47805
      8 Gertrudis-Kliniken im Parkinson-Zentrum Leun Germany 35638
      9 Neurologischische Arztpraxis Rostock Germany 18057
      10 Universitätsklinikum Rostock, Klinik für Neurologie Rostock Germany 18147
      11 Klinikverbund Südwest, Klinikum Sindelfingen-Böblingen Sindelfingen Germany 71085
      12 HANSE-Klinikum, Department of Neurology Stralsund Germany 18410
      13 University of Ulm, Department of Neurology Ulm Germany 89081
      14 Stiftung Deutsche Klinik für Diagnostik GmbH Fachbereich Neurologie Wiesbaden Germany 65191
      15 Chulalongkorn University Hospital Bangkok Thailand 10330

      Sponsors and Collaborators

      • CENTOGENE GmbH Rostock

      Investigators

      • Principal Investigator: Arndt Rolfs, MD, University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      CENTOGENE GmbH Rostock
      ClinicalTrials.gov Identifier:
      NCT01272687
      Other Study ID Numbers:
      • PD02/2011
      First Posted:
      Jan 10, 2011
      Last Update Posted:
      Apr 9, 2021
      Last Verified:
      Apr 1, 2020

      Study Results

      No Results Posted as of Apr 9, 2021